Daniel LaBarbera
Concepts (295)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Helicases | 7 | 2025 | 138 | 4.690 |
Why?
| | DNA-Binding Proteins | 10 | 2025 | 1473 | 4.030 |
Why?
| | Antineoplastic Agents | 13 | 2025 | 2152 | 1.990 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 792 | 1.780 |
Why?
| | Spheroids, Cellular | 4 | 2020 | 75 | 1.520 |
Why?
| | Neoplasms | 6 | 2025 | 2687 | 1.490 |
Why?
| | Epithelial-Mesenchymal Transition | 6 | 2025 | 210 | 1.450 |
Why?
| | Aldehyde Reductase | 7 | 2018 | 31 | 1.370 |
Why?
| | Drug Discovery | 7 | 2022 | 144 | 1.310 |
Why?
| | Cell Line, Tumor | 22 | 2025 | 3397 | 1.300 |
Why?
| | Drug Screening Assays, Antitumor | 8 | 2020 | 193 | 1.230 |
Why?
| | DNA Topoisomerases, Type II | 5 | 2019 | 44 | 1.130 |
Why?
| | Topoisomerase II Inhibitors | 3 | 2019 | 26 | 1.130 |
Why?
| | Drug Synergism | 3 | 2025 | 367 | 1.090 |
Why?
| | Acridines | 3 | 2014 | 7 | 1.090 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 850 | 1.040 |
Why?
| | DNA Damage | 3 | 2024 | 422 | 1.030 |
Why?
| | Cell Survival | 6 | 2024 | 1126 | 1.030 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 116 | 0.930 |
Why?
| | Hydrolyzable Tannins | 4 | 2014 | 5 | 0.930 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2022 | 254 | 0.910 |
Why?
| | Cell Cycle Checkpoints | 1 | 2025 | 97 | 0.880 |
Why?
| | Breast Neoplasms | 6 | 2025 | 2283 | 0.870 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 413 | 0.850 |
Why?
| | TCF Transcription Factors | 2 | 2020 | 17 | 0.800 |
Why?
| | Antigens, Neoplasm | 3 | 2016 | 316 | 0.800 |
Why?
| | Plant Extracts | 2 | 2017 | 209 | 0.780 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 157 | 0.760 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2024 | 870 | 0.750 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2024 | 203 | 0.710 |
Why?
| | Small Molecule Libraries | 4 | 2020 | 94 | 0.710 |
Why?
| | Imidazoles | 5 | 2021 | 239 | 0.660 |
Why?
| | Cell Plasticity | 1 | 2021 | 37 | 0.660 |
Why?
| | Clonal Evolution | 1 | 2020 | 45 | 0.630 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 433 | 0.620 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 365 | 0.610 |
Why?
| | Histones | 1 | 2023 | 632 | 0.560 |
Why?
| | Naegleria fowleri | 1 | 2017 | 1 | 0.550 |
Why?
| | Larrea | 1 | 2017 | 1 | 0.550 |
Why?
| | Entamoeba histolytica | 1 | 2017 | 10 | 0.550 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 16 | 0.540 |
Why?
| | Giardia lamblia | 1 | 2017 | 23 | 0.530 |
Why?
| | Drug Design | 5 | 2022 | 165 | 0.530 |
Why?
| | Neoplastic Stem Cells | 4 | 2020 | 397 | 0.500 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2016 | 26 | 0.490 |
Why?
| | Apoptosis | 8 | 2024 | 2551 | 0.490 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 563 | 0.460 |
Why?
| | Adenosine Triphosphate | 3 | 2019 | 490 | 0.450 |
Why?
| | Hepatocytes | 1 | 2015 | 211 | 0.440 |
Why?
| | Colonic Neoplasms | 2 | 2016 | 247 | 0.440 |
Why?
| | Porifera | 3 | 2009 | 8 | 0.440 |
Why?
| | Amidines | 1 | 2013 | 14 | 0.420 |
Why?
| | Heterocyclic Compounds | 1 | 2013 | 22 | 0.420 |
Why?
| | beta Catenin | 1 | 2016 | 253 | 0.420 |
Why?
| | Humans | 42 | 2025 | 138972 | 0.420 |
Why?
| | Glycosides | 1 | 2013 | 37 | 0.410 |
Why?
| | Amides | 1 | 2013 | 97 | 0.400 |
Why?
| | Adenocarcinoma | 1 | 2020 | 882 | 0.400 |
Why?
| | Cell Proliferation | 8 | 2025 | 2480 | 0.400 |
Why?
| | Animals | 21 | 2025 | 37243 | 0.390 |
Why?
| | Phyllanthus emblica | 1 | 2012 | 1 | 0.380 |
Why?
| | Retinoids | 1 | 2012 | 34 | 0.380 |
Why?
| | Mice | 15 | 2024 | 17828 | 0.360 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 748 | 0.350 |
Why?
| | Fruit | 1 | 2012 | 146 | 0.350 |
Why?
| | Promoter Regions, Genetic | 7 | 2022 | 1235 | 0.330 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1395 | 0.320 |
Why?
| | Keratin-5 | 3 | 2017 | 49 | 0.320 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2011 | 134 | 0.320 |
Why?
| | Transcription, Genetic | 3 | 2021 | 1471 | 0.320 |
Why?
| | Telomerase | 2 | 2022 | 247 | 0.310 |
Why?
| | Alkaloids | 1 | 2009 | 32 | 0.310 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 801 | 0.290 |
Why?
| | Thyroid Carcinoma, Anaplastic | 2 | 2019 | 33 | 0.280 |
Why?
| | Quinoxalines | 2 | 2007 | 67 | 0.280 |
Why?
| | Caspases | 1 | 2009 | 245 | 0.280 |
Why?
| | Catalytic Domain | 2 | 2023 | 227 | 0.280 |
Why?
| | Models, Biological | 3 | 2017 | 1810 | 0.280 |
Why?
| | Models, Molecular | 6 | 2015 | 1597 | 0.280 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2021 | 221 | 0.280 |
Why?
| | Molecular Structure | 6 | 2016 | 498 | 0.260 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2006 | 122 | 0.250 |
Why?
| | Thyroid Neoplasms | 2 | 2021 | 324 | 0.240 |
Why?
| | Receptors, Progesterone | 3 | 2017 | 349 | 0.220 |
Why?
| | Structure-Activity Relationship | 4 | 2019 | 570 | 0.210 |
Why?
| | Oncogenes | 2 | 2022 | 118 | 0.210 |
Why?
| | Poly ADP Ribosylation | 1 | 2023 | 10 | 0.210 |
Why?
| | Fluorouracil | 1 | 2024 | 204 | 0.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1742 | 0.210 |
Why?
| | Benzimidazoles | 1 | 2005 | 177 | 0.210 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1229 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 50 | 0.200 |
Why?
| | Progesterone | 3 | 2017 | 258 | 0.200 |
Why?
| | Indoles | 1 | 2006 | 411 | 0.190 |
Why?
| | Integrins | 1 | 2022 | 95 | 0.180 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2021 | 18 | 0.180 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 667 | 0.170 |
Why?
| | Female | 11 | 2025 | 74016 | 0.170 |
Why?
| | HEK293 Cells | 3 | 2012 | 731 | 0.170 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 15 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 150 | 0.170 |
Why?
| | Carcinogenesis | 1 | 2022 | 215 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2020 | 80 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 183 | 0.160 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.160 |
Why?
| | Mutation | 5 | 2022 | 3984 | 0.160 |
Why?
| | Binding, Competitive | 1 | 2019 | 196 | 0.160 |
Why?
| | HIV Protease | 1 | 2019 | 4 | 0.150 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 329 | 0.150 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2022 | 248 | 0.150 |
Why?
| | Cell Cycle | 2 | 2014 | 593 | 0.150 |
Why?
| | Depsipeptides | 2 | 2011 | 14 | 0.150 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 163 | 0.150 |
Why?
| | Organoids | 1 | 2020 | 119 | 0.150 |
Why?
| | Glioblastoma | 1 | 2022 | 342 | 0.150 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.150 |
Why?
| | Nuclear Proteins | 1 | 2023 | 707 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 68 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2020 | 192 | 0.140 |
Why?
| | Drug Resistance | 1 | 2019 | 149 | 0.140 |
Why?
| | alpha-Glucosidases | 1 | 2018 | 9 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 197 | 0.140 |
Why?
| | Solanum tuberosum | 1 | 2018 | 7 | 0.140 |
Why?
| | alpha-Amylases | 1 | 2018 | 16 | 0.140 |
Why?
| | Polyphenols | 1 | 2018 | 19 | 0.140 |
Why?
| | Masoprocol | 1 | 2017 | 3 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 897 | 0.140 |
Why?
| | Naphthols | 1 | 2017 | 7 | 0.140 |
Why?
| | Viral Nonstructural Proteins | 1 | 2018 | 65 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 262 | 0.140 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 17 | 0.140 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 42 | 0.130 |
Why?
| | Mice, Nude | 3 | 2021 | 688 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 206 | 0.130 |
Why?
| | Chikungunya virus | 1 | 2018 | 80 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1355 | 0.130 |
Why?
| | Emodin | 1 | 2016 | 3 | 0.130 |
Why?
| | Receptors, Estrogen | 3 | 2017 | 437 | 0.120 |
Why?
| | Transcriptome | 1 | 2022 | 966 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2047 | 0.120 |
Why?
| | Marine Toxins | 1 | 2015 | 12 | 0.120 |
Why?
| | Xanthines | 1 | 2015 | 23 | 0.120 |
Why?
| | Biological Products | 2 | 2011 | 226 | 0.120 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 50 | 0.120 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4316 | 0.120 |
Why?
| | Tretinoin | 2 | 2017 | 123 | 0.120 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 136 | 0.120 |
Why?
| | Sorbitol | 2 | 2012 | 14 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.120 |
Why?
| | Down Syndrome | 1 | 2022 | 483 | 0.120 |
Why?
| | Progestins | 2 | 2012 | 80 | 0.110 |
Why?
| | Retinal Pigments | 1 | 2014 | 6 | 0.110 |
Why?
| | Virus Replication | 1 | 2018 | 526 | 0.110 |
Why?
| | Microglia | 2 | 2014 | 256 | 0.110 |
Why?
| | Acid Phosphatase | 1 | 2014 | 20 | 0.110 |
Why?
| | Rhodamines | 1 | 2014 | 20 | 0.110 |
Why?
| | G2 Phase | 1 | 2014 | 39 | 0.110 |
Why?
| | Lens, Crystalline | 2 | 2016 | 132 | 0.110 |
Why?
| | Neoplasm Transplantation | 2 | 2019 | 249 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2016 | 198 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 224 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 501 | 0.110 |
Why?
| | Quinones | 1 | 2013 | 9 | 0.110 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.100 |
Why?
| | Cataract | 1 | 2016 | 221 | 0.100 |
Why?
| | Transcription Factors | 1 | 2021 | 1701 | 0.100 |
Why?
| | Endotoxins | 1 | 2014 | 220 | 0.100 |
Why?
| | Retinal Diseases | 1 | 2014 | 96 | 0.100 |
Why?
| | Green Fluorescent Proteins | 2 | 2012 | 398 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 990 | 0.100 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.100 |
Why?
| | Miconazole | 1 | 2012 | 5 | 0.100 |
Why?
| | Isotretinoin | 1 | 2012 | 24 | 0.100 |
Why?
| | Hydrobromic Acid | 1 | 2012 | 1 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2020 | 2815 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 733 | 0.090 |
Why?
| | Luciferases | 1 | 2012 | 150 | 0.090 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 102 | 0.090 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 82 | 0.090 |
Why?
| | Eye | 1 | 2012 | 112 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 89 | 0.090 |
Why?
| | Retina | 1 | 2014 | 304 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 194 | 0.090 |
Why?
| | Genes, Reporter | 1 | 2012 | 274 | 0.090 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 168 | 0.090 |
Why?
| | Oxazoles | 1 | 2011 | 36 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2014 | 357 | 0.080 |
Why?
| | Vimentin | 1 | 2011 | 52 | 0.080 |
Why?
| | Software | 1 | 2015 | 670 | 0.080 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 956 | 0.080 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1090 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 513 | 0.080 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 888 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2022 | 4182 | 0.070 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 174 | 0.070 |
Why?
| | Macrophages | 2 | 2014 | 1543 | 0.070 |
Why?
| | Epithelial Cells | 1 | 2014 | 1103 | 0.070 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 1076 | 0.070 |
Why?
| | Stereoisomerism | 1 | 2007 | 105 | 0.070 |
Why?
| | Computer Simulation | 1 | 2012 | 995 | 0.070 |
Why?
| | Heat-Shock Response | 1 | 2008 | 75 | 0.070 |
Why?
| | Hydrocarbons, Halogenated | 1 | 2007 | 5 | 0.070 |
Why?
| | Quinolines | 1 | 2008 | 150 | 0.070 |
Why?
| | Beauveria | 1 | 2006 | 2 | 0.060 |
Why?
| | Mycotoxins | 1 | 2006 | 4 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 230 | 0.060 |
Why?
| | Pyrroles | 1 | 2007 | 210 | 0.060 |
Why?
| | Fungal Proteins | 1 | 2006 | 136 | 0.060 |
Why?
| | Protein Binding | 1 | 2012 | 2233 | 0.060 |
Why?
| | Quinolones | 1 | 2007 | 135 | 0.060 |
Why?
| | Solutions | 1 | 2006 | 168 | 0.060 |
Why?
| | Peptides, Cyclic | 1 | 2007 | 265 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 5801 | 0.060 |
Why?
| | Catalysis | 1 | 2006 | 320 | 0.060 |
Why?
| | Imidazolidines | 2 | 2014 | 10 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 557 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 850 | 0.050 |
Why?
| | Melanoma, Experimental | 1 | 2005 | 111 | 0.050 |
Why?
| | Models, Chemical | 1 | 2005 | 270 | 0.050 |
Why?
| | Oxidative Stress | 2 | 2022 | 1318 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2022 | 33 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1649 | 0.050 |
Why?
| | Inflammation | 1 | 2012 | 2853 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 24 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2014 | 627 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 67 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2021 | 276 | 0.040 |
Why?
| | Mass Spectrometry | 2 | 2018 | 739 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2020 | 92 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 139 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 322 | 0.040 |
Why?
| | Depsides | 1 | 2018 | 2 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 345 | 0.040 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2020 | 259 | 0.040 |
Why?
| | Salicylates | 1 | 2018 | 29 | 0.040 |
Why?
| | RNA Caps | 1 | 2018 | 33 | 0.040 |
Why?
| | Vero Cells | 1 | 2018 | 87 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2879 | 0.040 |
Why?
| | Proteolysis | 1 | 2019 | 176 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 46 | 0.030 |
Why?
| | Cricetinae | 1 | 2018 | 297 | 0.030 |
Why?
| | Lactones | 1 | 2018 | 58 | 0.030 |
Why?
| | Anthocyanins | 1 | 2018 | 32 | 0.030 |
Why?
| | Fluorescence | 1 | 2018 | 159 | 0.030 |
Why?
| | Stem Cells | 1 | 2021 | 599 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 305 | 0.030 |
Why?
| | Gene Frequency | 1 | 2018 | 501 | 0.030 |
Why?
| | Aldo-Keto Reductases | 1 | 2016 | 1 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2019 | 462 | 0.030 |
Why?
| | Colchicine | 1 | 2015 | 23 | 0.030 |
Why?
| | Tubulin Modulators | 1 | 2015 | 10 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 449 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 322 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 111 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 453 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 907 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 73 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2009 | 10921 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 145 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1994 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1370 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 133 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 650 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 24 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2017 | 539 | 0.020 |
Why?
| | MCF-7 Cells | 1 | 2012 | 123 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 193 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 280 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1232 | 0.020 |
Why?
| | Uveitis | 1 | 2012 | 146 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 1261 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1317 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2171 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1730 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 969 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3995 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 1031 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1192 | 0.020 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2008 | 46 | 0.020 |
Why?
| | Toxicity Tests, Acute | 1 | 2007 | 8 | 0.020 |
Why?
| | Marine Biology | 1 | 2007 | 4 | 0.020 |
Why?
| | Fiji | 1 | 2007 | 3 | 0.020 |
Why?
| | Antibiotics, Antitubercular | 1 | 2006 | 36 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2006 | 91 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 2083 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 611 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 342 | 0.010 |
Why?
| | Binding Sites | 1 | 2008 | 1317 | 0.010 |
Why?
| | Signal Transduction | 1 | 2017 | 5092 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 315 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 497 | 0.010 |
Why?
| | Aged | 1 | 2019 | 24172 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 33782 | 0.010 |
Why?
| | Male | 1 | 2012 | 68250 | 0.000 |
Why?
|
|
LaBarbera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|